[Clinical significance of the determination of oxidation and acetylation phenotype in patients with multiple sclerosis].
Genetically determined individual differences in the ability of oxidation and acetylation of certain drugs have raised in recent years a considerable interest in view of their clinical importance. The purpose of the study was finding out of a possible difference in the ability to oxidized sparteine and to acetylate sulfamidine as model drugs between patients with multiple sclerosis and healthy control volunteers. The study was carried out in 23 patients with MS. The control group comprised 160 healthy subjects for comparison of oxidation phenotype. The results of determination of acetylation phenotype were obtained in 45 healthy controls. The study showed that in 160 controls 146 were extensive (rapid) metabolizers (91.3%) and 14 were weak (slow) metabolizers of sparteine (8.7%). In the group of MS patients 21 were extensive metabolizers (91.3%) and 2 were weak metabolizers (8.7%). The determination of acetylation phenotype in 45 controls showed 51% of rapid acetylation (23 subjects) and 49% of slow acetylation (22.